IACP Breaking News
IACP Presents at JCPP on Constructive Transfer
August 31, 2012 -- Yesterday morning, August 30th, IACP updated the Joint Commission of Pharmacy Practitioners (JCPP) about the ongoing issue of controlled substance constructive transfer which affects all pharmacists – not just compounders. JCPP was formed in 1977 as a forum on matters of common interest and concern to national organizations of pharmacy practitioners and invited liaison members.
“Although IACP has taken the lead responsibility for resolving the constructive transfer problem, we’re doing it as a collaboration with our colleagues in other associations as well,” says Sarah Dodge, IACP’s vice-president of government affairs. “The refusal of the Drug Enforcement Administration (DEA) to address its policies and their inherent conflicts with medical practice, the clinical decision making process of pharmacists and prescribers, and the preservation of drug integrity for patient safety impacts every type of practice.”
While compounding pharmacists first uncovered this problem through working with pain management clinics that administer intrathecal medications and veterinarians who have patients in a variety of settings, constructive transfer – the ability to deliver a patient-specific controlled substance prescription to the patient’s prescriber for administration – it also affects traditional community, health-system, home infusion, long term care, hospice, and managed care.
“We have made great progress in bringing Congressional pressure on the DEA to engage with the profession in formal rule-making,” said IACP Executive Vice President and CEO David Miller, RPh, in his remarks before the JCPP. “That is directly due to the collaboration between all our organizations, working cohesively to resolve a genuine problem that affects each of our members.”
Return to IACP Home Page